Recent Events - Dr. Andrew Blitzer (MD, DDS, FACS Director Research AND LLC)


  • Past-President, American Laryngological Society
  • Past-President, American Bronchoesophagological Association

Advisory Committees

  • Allergan, Inc Cosmetic Botulinum toxins and injectable fillers
  • Merz Pharmaceuticals - Botulinum toxins for Therpeutic Indications
  • Revance Pharmaceuticals- Botulinum toxins for cosmetic indications
  • Lisa Lasers- Thullium lasers for rhinologic and laryngologic indications

Recent Book Publications

  • Neurologic Disorders of the Larynx- 2nd edition, Thieme Medical Publishers
  • Botulinum Neurotoxin for Head and Neck Disorders, Thieme Medical Publishers

Invited Speaker

  • International Voice Symposium
  • Seoul Korea, 2012

Visiting Professor/Lectures

  • The Blanchard-Kleinman Lecturer
  • University of Maryland, June, 2009
  • The Goldman/Biller Lecturer
  • Mt. Sinai School of Medicine, June 2009
  • The Steven Gray Memorial Lecture
  • The University of Utah, June 2009
  • The J. Floyd Kyser, MD Lecturer
  • The University of Arkansas, June, 2011
  • The 2nd Clyde B Alley Lecturer
  • Vanderbilt University, December 2011


  • International Laser in Laryngology Symposium Paris, France April 2010

Guest Faculty

  • European Dystonia Meeting Hanover, Germany May 2010


  • World Voice Meeting Seuol, Korea August 2010


  • Laryngology and Voice Surgery Harvard Medical School, Boston, September, 2010.

Currently running Research Projects:

  • Co- Investigator Double-Blind, placebo controlled study of the use Botox (Botulinum toxin A) for the management of Trigeminal Neuraligia 2006 to 2011 PI- David Sirois, DDS, PhD (NYU)
  • Co-Investigator DNA analysis for spontaneous mutations in Idiopathic focal dystonia PI- Mark LeDoux, MD, PhD (U. Tenn-Memphis)
  • Co-Investigator Merz Pharmaceuticals Prospective, double-blind, placebo controlled, randomized, multi-center trial with open-label Extension Period to investigate the efficacy and safety of different doses of NT 201 in the treatment of blepharospasm 2007 to 2009.
  • Co-Investigator Revance Therapeutics Prospective, double-blind, placebo controlled, randomized trial of a polypeptide-botulinum toxin complex for the management of lateral canthal lines 2008-2010
  • Principle Investigator 25 year DataBase for Botulinum toxin therapy safety and efficacy- Unrestricted Research Funding- Allergan, Inc 2011 to present
  • Principle Investigator Prospective, double-blind, placebo controlled, randomized trial of Xeomin (Botulinum toxin A)for the Treatment of Subjects with Painful Temporomandibular Disorders (TMD) Unrestricted Research Funding- Merz Pharmaceuticals 2011 to present
  • Co-Investigator Dystonia Coalition Projects - Spasmodic Dysphonia Christy Ludlow, PhD and Buzz Jinnah, MD, PhD Principle Investigators